Peptides
Semaglutide's Cardiovascular Dividend: What the Latest Meta-Analyses Reveal
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.
GLP-1
Metabolic Health
GLP-1s After Gastric Bypass: The First Real Trial for Weight Regain Just Landed
A 56-week randomized trial finally tests what patients and surgeons have been doing off-script: adding liraglutide when the scale starts climbing again after bypass.
Metabolic Health
Lifestyle Still Wins: The 2025 Case for Diet, Exercise and the Metabolic Trio
A major Herz review reaffirms that Mediterranean eating, structured movement and smoking cessation move the endpoints that matter — a useful corrective in the GLP-1 era.
Peptides
The Next GLP-1s: Dual Fatty-Acid Conjugates and Combo Therapies Push Past Semaglutide
Two 2025 preclinical studies hint at where this class is heading — longer-acting molecules, beta-cell-protective stacks, and the first real challengers to semaglutide's throne.
Peptides
Why GLP-1 Drugs Last for Days: The Lipid Trick Behind Semaglutide's Half-Life
Native GLP-1 vanishes from your bloodstream in minutes. A fatty-acid tail turns it into a once-weekly shot — but the same trick that buys time also makes the drug harder to manufacture.
Metabolic Health
The Muscle Question: What Sarcopenic Obesity and Diabetes Drugs Mean for Aging Well
Two new studies reframe the conversation around metabolic health in later life — pointing to skeletal muscle, mitochondria, and medication choice as the quiet variables that matter.
Metabolic Health
Obesity as an Accelerator of Cardiovascular Aging — And Why Weight Loss May Buy You Time
A major European Heart Journal review reframes excess weight as a driver of the heart's biological aging itself. The implication: weight reduction may be less about preventing one bad day and more about extending healthy years.
Peptides
The GLP-1 Side-Effect File: New Signals on Surgery, Pancreatitis, and the Gallbladder
Semaglutide and tirzepatide are reshaping body composition for millions of lifters and dieters. A cluster of 2025 reports is starting to map what happens when these drugs collide with surgery, scopes, and scans.
Metabolic Health
GLP-1s Beyond Weight Loss: Kidneys, Taste Buds, and What the Real-World Data Actually Show
A multinational cohort sketches who's really starting GLP-1s for diabetes and kidney disease — and a new mouse study hints these drugs may rewire taste itself.
Medical Research
Patents, Product Hops, and the Coming GLP-1 Affordability Cliff
A new legal analysis warns that the same patent playbook that kept inhalers expensive for decades is now being run on GLP-1 drugs — just as millions of women are lining up for them.